Navigation Links
Schering-Plough CEO Buys $2 Million in Common Shares
Date:4/24/2008

KENILWORTH, N.J., April 24 /PRNewswire-FirstCall/ -- Schering-Plough Corporation announced today that Chairman and CEO Fred Hassan purchased just over $2 million of Schering-Plough common stock, or 110, 000 shares at an average purchase price of $18.26 per share.

"As I said when I announced my intention to purchase these shares in January, this investment in Schering-Plough reflects my long-term confidence in the company, its products -- including ZETIA and VYTORIN -- and our late- stage pipeline," said Hassan.

Hassan has said on January 18 that he intended to purchase the shares as soon as the transaction received legal clearance. That clearance was issued this morning, based upon first quarter earnings having been reported yesterday.

Full details of the purchase will be reported on a Form 4 filed with the SEC and available on Schering-Plough's Web site today or tomorrow.

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is http://www.schering-plough.com.


'/>"/>
SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Schering-Plough Announces Planned Divestiture of Select Animal Health Products in Europe
2. Schering-Plough Reports Financial Results for First Quarter of 2008
3. Schering-Plough Schedules Conference Call and Webcast for 2008 First Quarter Earnings
4. Schering-Plough Launches Productivity Transformation Program To Confront New Challenges
5. Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
6. Schering-Plough Announces Filing of U.S. Application for OTC ZEGERID(R)
7. Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year
8. Schering-Plough and OraSure Technologies Sign International Collaboration for Rapid Point-of-Care Oral Hepatitis C Test
9. Schering-Plough Announces Organizational Changes at Schering-Plough Research Institute
10. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
11. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... BILLERICA, Mass. , Jan. 24, 2017 ... acquired Hysitron, Inc., a technology leader in ... test instrumentation. The acquisition adds Hysitron,s innovative ... of atomic force microscopes (AFMs), surface profilometers, ... enhancing Bruker,s leadership position in nanomaterials research ...
(Date:1/24/2017)... Jan. 24, 2017 /PRNewswire/ - BioAmber Inc. (NYSE: ... have agreed to increase the size of the offering by ... Company, together with warrants to purchase 1,842,106 shares of common ... per share of common stock (the "Exercise Price"), at a ... warrant (the "Public Price"). The warrants have a term of ...
(Date:1/24/2017)... ... January 24, 2017 , ... Men who ... leptin levels had a positive association with increased prostate growth or benign prostatic ... International Neurourology Journal involved 571 Korean men who underwent urological examinations, including ...
(Date:1/24/2017)... Switerland (PRWEB) , ... January 24, 2017 , ... ... first commercially available malaria Plasmodium falciparum culture panels with standard concentrations of histidine ... which are available in a range of concentrations from six different malaria strains, ...
Breaking Biology Technology:
(Date:1/18/2017)... , Jan. 18, 2017  In vitro diagnostic (IVD) ... mergers and acquisitions (M&A), and Kalorama Information expects that ... acquisitions have been shifting. Generally, uncertainty in reimbursement and ... the U.S. has changed the acquisitions landscape. Instead of ... in companies buying partners outside of their home country ...
(Date:1/13/2017)... Jan. 13, 2017 Sandata Technologies, LLC, ... the homecare industry, including Electronic Visit Verification™ (EVV™), ... Justin Jugs, as Senior Vice President of Product ... years of homecare experience to Sandata, where he ... plans to align Sandata,s suite of solutions with ...
(Date:1/12/2017)... research undertaken by Fit Small Business has revealed ... simply asked which office technology had they not used in ... Insights on what will be key features in ... industry leaders including Penelope Trunk , Martin Lindstrom ... Some of these findings included; ...
Breaking Biology News(10 mins):